These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27076146)

  • 1. An Approach to Identify and Characterize a Subunit Candidate Shigella Vaccine Antigen.
    Pore D; Chakrabarti MK
    Methods Mol Biol; 2016; 1403():433-44. PubMed ID: 27076146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response.
    Mukhopadhaya A; Mahalanabis D; Chakrabarti MK
    Vaccine; 2006 Aug; 24(33-34):6028-36. PubMed ID: 16765491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant.
    Pastor Y; Camacho AI; Zúñiga-Ripa A; Merchán A; Rosas P; Irache JM; Gamazo C
    Vaccine; 2018 Nov; 36(49):7509-7519. PubMed ID: 30420041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shigella vaccine development: prospective animal models and current status.
    Kim YJ; Yeo SG; Park JH; Ko HJ
    Curr Pharm Biotechnol; 2013; 14(10):903-12. PubMed ID: 24372251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate.
    Pore D; Chakrabarti MK
    Vaccine; 2013 Aug; 31(36):3644-50. PubMed ID: 23764536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies.
    Camacho AI; Souza-Rebouças J; Irache JM; Gamazo C
    Methods; 2013 May; 60(3):264-8. PubMed ID: 23046911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
    Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
    Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivated and subunit vaccines to prevent shigellosis.
    Kaminski RW; Oaks EV
    Expert Rev Vaccines; 2009 Dec; 8(12):1693-704. PubMed ID: 19943764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico analysis and recombinant expression of BamA protein as a universal vaccine against Escherichia coli in mice.
    Guan Q; Wang X; Wang X; Teng D; Wang J
    Appl Microbiol Biotechnol; 2016 Jun; 100(11):5089-98. PubMed ID: 27020285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
    Yagnik B; Sharma D; Padh H; Desai P
    Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strain.
    Mitra S; Sinha R; Mitobe J; Koley H
    Vaccine; 2016 Apr; 34(15):1839-46. PubMed ID: 26878295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing and evaluation of an antibody-targeted chimeric recombinant vaccine encoding Shigella flexneri outer membrane antigens.
    Kazi A; Hisyam Ismail CMK; Anthony AA; Chuah C; Leow CH; Lim BH; Banga Singh KK; Leow CY
    Infect Genet Evol; 2020 Jun; 80():104176. PubMed ID: 31923724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress towards development of a Shigella vaccine.
    Camacho AI; Irache JM; Gamazo C
    Expert Rev Vaccines; 2013 Jan; 12(1):43-55. PubMed ID: 23256738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.
    Kämpf MM; Braun M; Sirena D; Ihssen J; Thöny-Meyer L; Ren Q
    Microb Cell Fact; 2015 Jan; 14():12. PubMed ID: 25612741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a.
    Pore D; Chowdhury P; Mahata N; Pal A; Yamasaki S; Mahalanabis D; Chakrabarti MK
    Vaccine; 2009 Sep; 27(42):5855-64. PubMed ID: 19660587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
    Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
    Vaccine; 2014 Nov; 32(49):6659-66. PubMed ID: 25240754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity.
    Pahil S; Taneja N; Ansari HR; Raghava GPS
    PLoS One; 2017; 12(8):e0180505. PubMed ID: 28767653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV; Roberts F; Verma NK
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.